About lebrikizumab
Interleukin-13 inhibitor
Used for
- Treats moderate-to-severe atopic dermatitis (eczema) in eligible adults and adolescents.
Usual adult dose
500 mg initially and at week 2, then 250 mg every two weeks until clear or nearly clear; maintenance may be every four weeks.
Usual dose in children
Adolescents aged 12 years or older and weighing at least 40 kg: same schedule as adults.
Common side effects
- Injection-site reactions
- Conjunctivitis or eye inflammation
- Dry eye
- Herpes infections, including cold sores
Important warnings
- Avoid live vaccines during treatment.
- Eye inflammation may require assessment and treatment.
- Seek medical review for signs of serious infection or allergic reaction.
- Do not use with other biologic immunosuppressants unless specifically directed.
Pregnancy
Human pregnancy data are limited; use requires weighing potential benefits against uncertain risks.
Breastfeeding
It is unknown whether lebrikizumab passes into breast milk; clinical effects are uncertain.
Interactions
- Live vaccines may be less safe or effective during treatment.
- Other biologic immunosuppressants may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.